Study of TRX-920 for Patients With Advanced Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title:

A Phase I, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TRX-920 Oral Gel (10 mg and 30 mg) in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06143774
• Other study ID #: SNOF-001
• Status: Recruiting
• Phase: Phase 1
• Start date: October 31, 2023
• Est. completion date: January 31, 2026

Study information

• Verified date: November 2023
• Source: TaiRx, Inc.
• Contact: Yen-Ling Chen, Ph.D.
• Phone: +886226535007
• Email: yenlingchen[@]trx.com.tw
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study drug TRX-920 Oral Gel contains SN38, an active metabolite of Irinotecan (CPT-11), which is a widely prescribed anti-cancer drug that has been approved in many countries for the treatment of colorectal and pancreatic cancer. TRX-920 is the oral gel formulation that directly contains SN38 instead of Irinotecan. A series of biology and animal studies have demonstrated that the TRX-920 Oral Gel could inhibit tumor growth with fewer side effects compared to Irinotecan.

Description:

This is the first study in which the study drug TRX-920 Oral Gel is being given to humans. However, as a metabolite of Irinotecan, SN38 has proved its effectiveness in the treatment of colorectal and pancreatic cancer. TRX-920 also showed its effect of anti-tumor in various cancer cell lines and animal models. The purposes of this study are to find the highest dose of the study drug that can be given without causing significant side effects, the side effect of the study drug, the concentration of the study drug in the blood, and the effect on your specific cancer. The clinical study will be conducted in Taiwan. The drug used in this study is an investigational product (TRX-920 Oral Gel) which is provided free of charge by TaiRx, Inc. (a pharmaceutical company in Taiwan, and is the sponsor of this study), and is a potential oral anti-cancer therapy for patients suffering from various cancers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: January 31, 2026
• Est. primary completion date: December 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

Subjects must meet all of the following criteria to be eligible for enrollment in the

study:

1. Signed and dated informed consent form

2. Histologically and cytologically confirmed advanced solid tumor malignancies that are refractory to standard therapy or have no accepted standard therapy.

3. Solid tumors that are measurable or evaluable as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Target lesions that have been previously irradiated will not be considered measurable (lesion).

4. Female or male, 18 years of age or older.

5. ECOG performance status 0 or 1.

6. QTcF = 480 ms at screening.

Exclusion Criteria:

1. Patients with homozygous or compound heterozygous genotypes for UGT1A1*28 and *6 alleles (e.g., *28/*28, *6/*6, *6/*28).

2. Clinically significant comorbidity such as unstable angina, congestive heart failure (NYHA Grade III or IV), uncontrolled hypertension (>160/100 mmHg despite optimal medical treatment), chronic obstructive pulmonary disease (COPD) with frequent exacerbations, refractory asthma, inflammatory bowel disease or intestinal obstruction.

3. Acute myocardial infraction or cerebrovascular accident (CVA) within 6 months prior the first dose of study drug.

4. Central nervous system (CNS) metastasis or seizure disorder due to underlying malignancy except those who have been treated and have stable CNS metastases or are asymptomatic.

5. AIDS-defining opportunistic infections within the past 12 months.

6. HBV infection (positive HBsAg) except for carrier of inactive HBV as defined by negative HBeAg with normal ALT and HBV DNA < 2,000 IU/mL or HCV infection (positive anti-HCV antibody) except for those with undetectable HCV RNA.

7. Inadequate bone marrow reserve, hepatic or renal function as defined by any of the

following laboratory values:

1. absolute neutrophil count (ANC) < 1500/µL

2. platelet count < 90,000/µL

3. hemoglobin < 9 g/dL

4. total bilirubin > 1.5*the upper limit of normal (ULN)

5. aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3*ULN if no hepatic metastases are present; > 5*ULN if hepatic metastases are present

6. Non-indexed eGFR < 60 mL/min (formula in Appendix 4)

8. Toxicities resulting from prior therapy or surgical procedures not yet resolved to = NCI CTCAE v5.0 Grade 1 with the exception of alopecia, skin hyperpigmentation or hypopigmentation or grade 2 toxicity with prior approval of the Medical Monitor.

9. Major surgical procedures (as defined by Investigator) within 4 weeks prior to the first dose of study drug or any ongoing post-operative complications.

10. Receiving any radiotherapy within 3 months

11. Receiving any (investigational or approved) anti-cancer therapy (including chemotherapy or targeted therapy) within 28 days or 5 half-lives (whichever is longer) prior to the first dose of study drug

12. A history of apparent allergic reactions to irinotecan injection (dosed with prior treatment with prophylactic drug)

13. If female, is pregnant or breastfeeding

14. If men or women with childbearing potential, unwilling to use effective contraceptive methods during the study and for at least 3 months (men) or 1 month (women) after the last dose of study drug. Effective contraceptive methods include implants, injectables, combined oral contraceptives, intra-uterine devices (IUDs), sexual abstinence, surgical sterilization, or a partner who is sterile.

15. Receiving live attenuated vaccine within 28 days prior to the first dose of study drug.

16. Life expectancy < 3 months.

17. Other prior or ongoing condition(s) that, in the opinion of the investigator, could affect the safety of the subject, compromise the subject's ability to comply with the study requirements or impair the assessment of study results.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms

Intervention

Drug:
• TRX-920 Oral Gel (10 mg and 30 mg)
TRX-920 Oral Gel will be administered orally at a week (BIW) in an 8-week cycle. No food should be taken 2 hours before and 1 hour after taking TRX-920. The dose escalation/de-escalation rules will be based on definitions of dose-limiting toxicity (DLT) and will be monitored during the first treatment cycle (i.e., the first 4 weeks post the first dose). The starting dose will be 1 mg and the dosing frequency is twice every week (BIW). Subjects will be assigned to a dose level in sequential cohorts based on the order of their enrollment. The dose escalation will follow a 3+3 design and doses escalate from approximately 1 mg BIW, 2 mg BIW, 4 mg BIW, 8 mg BIW, and 16mg BIW and the doses for subsequent cohorts will be determined by Safety Review Committee (SRC). Dose escalation will be stopped till the maximum tolerated dose (MTD) is reached or identified.

Locations

Country	Name	City	State
Taiwan	China Medical University Hospital	Taichung
Taiwan	Taipei Medical University Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
TaiRx, Inc.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of TRX-920 Oral Gel	The MTD is defined as the highest dose level at which no more than 1 in 6 subjects experiences a DLT. The recommended Phase 2 dose (RP2D) will be determined by Safety Review Committee based on all available PK, safety, and preliminary efficacy data. The RP2D will not exceed the MTD.	the first 4 weeks post the first dose
Primary	Frequency, type, severity and relationship to study drug of adverse events (AEs) of TRX-920 Oral Gel	AEs will be coded by system organ class (SOC) and preferred term according to the Medical Dictionary for Regulatory Activities (MedDRA) system.	Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days)
Secondary	Drug exposure and human pharmacokinetics (Cmax) of SN38 derived from plasma concentration-time profiles	The plasma concentrations of SN38 will be analyzed using compartmental or non-compartmental approach to calculate Cmax for individual subjects.	Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days)
Secondary	Drug exposure and human pharmacokinetics (Tmax) of SN38 derived from plasma concentration-time profiles	The plasma concentrations of SN38 will be analyzed using compartmental or non-compartmental approach to calculate Tmax for individual subjects.	Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days)
Secondary	Drug exposure and human pharmacokinetics (MRT) of SN38 derived from plasma concentration-time profiles	The plasma concentrations of SN38 will be analyzed using compartmental or non-compartmental approach to calculate MRT for individual subjects.	Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days)
Secondary	Drug exposure and human pharmacokinetics (AUC) of SN38 derived from plasma concentration-time profiles	The plasma concentrations of SN38 will be analyzed using compartmental or non-compartmental approach to calculate AUC for individual subjects.	Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days)
Secondary	Drug exposure and human pharmacokinetics (terminal half-life) of SN38 derived from plasma concentration-time profiles	The plasma concentrations of SN38 will be analyzed using compartmental or non-compartmental approach to calculate terminal half-life (T 1/2) for individual subjects.	Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days)
Secondary	Objective response rate (ORR) per RECIST v1.1	Tumor assessment by computed tomography (CT) or magnetic resonance imaging (MRI) will be performed every 8-week cycle starting from Cycle 2 Day 1. All subjects will attend an End of Treatment (EOT) visit at the time decision is made to discontinue study drug administration.; The Objective response rate (ORR) as per RECIST v1.1 will be calculated in the efficacy population.	Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days)
Secondary	Disease control rate (DCR) per RECIST v1.1	Tumor assessment by computed tomography (CT) or magnetic resonance imaging (MRI) will be performed every 8-week cycle starting from Cycle 2 Day 1. All subjects will attend an End of Treatment (EOT) visit at the time decision is made to discontinue study drug administration.; The disease control rate (DCR) as per RECIST v1.1 will be calculated in the efficacy population.	Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days)
Secondary	Duration of response (DOR) per RECIST v1.1	Tumor assessment by computed tomography (CT) or magnetic resonance imaging (MRI) will be performed every 8-week cycle starting from Cycle 2 Day 1. All subjects will attend an End of Treatment (EOT) visit at the time decision is made to discontinue study drug administration.; The duration or response (DOR) as per RECIST v1.1 will be calculated in the efficacy population.	Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days), assessed up to 24 months
Secondary	Time to tumor progression (TTP) per RECIST v1.1	Tumor assessment by computed tomography (CT) or magnetic resonance imaging (MRI) will be performed every 8-week cycle starting from Cycle 2 Day 1. All subjects will attend an End of Treatment (EOT) visit at the time decision is made to discontinue study drug administration.; The time to tumor progression (TTP) as per RECIST v1.1 will be calculated in the efficacy population.	Cycle 1 Day 1 to study completion, an average of 1 year (each cycle is 56 days), assessed up to 24 months